Does the media prefer DTIL or ALLO?

In the previous week, Precision BioSciences had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for Precision BioSciences and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.69 beat Precision BioSciences' score of 0.63 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RLMD or DTIL?

In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 4 articles in the media. Precision BioSciences' average media sentiment score of 0.63 beat Relmada Therapeutics' score of 0.57 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DTIL or CLYM?

In the previous week, Climb Bio had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 5 mentions for Climb Bio and 4 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.63 beat Climb Bio's score of 0.37 indicating that Precision BioSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ZSQR or DTIL?

Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 309.26%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Precision BioSciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Does the media favor ZSQR or DTIL?

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Coeptis Therapeutics and 4 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.63 beat Coeptis Therapeutics' score of 0.14 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DTIL or ACRS?

In the previous week, Precision BioSciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for Precision BioSciences and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Precision BioSciences' score of 0.63 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precision BioSciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Precision BioSciences (DTIL) Competitors

$7.88 +0.02 (+0.25%)

Closing price 07/1/2026 04:00 PM Eastern

Extended Trading

$7.88 0.00 (0.00%)

As of 07/1/2026 05:11 PM Eastern

Compare

DTIL vs. ALLO, RLMD, CLYM, ZSQR, and ACRS

Should you buy Precision BioSciences stock or one of its competitors? MarketBeat compares Precision BioSciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Precision BioSciences include Allogene Therapeutics (ALLO), Relmada Therapeutics (RLMD), Climb Bio (CLYM), Coeptis Therapeutics (ZSQR), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical products" industry.

How does Precision BioSciences compare to Allogene Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Precision BioSciences has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Precision BioSciences has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.93	-$45.72M	-$3.67	N/A
Allogene Therapeutics	$20K	36,413.33	-$190.89M	-$0.77	N/A

Precision BioSciences presently has a consensus price target of $32.25, suggesting a potential upside of 309.26%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 303.90%. Given Precision BioSciences' higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Precision BioSciences had 2 more articles in the media than Allogene Therapeutics. MarketBeat recorded 4 mentions for Precision BioSciences and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.69 beat Precision BioSciences' score of 0.63 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Allogene Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Allogene Therapeutics' return on equity of -56.45% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Allogene Therapeutics beats Precision BioSciences on 10 of the 17 factors compared between the two stocks.

How does Precision BioSciences compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 87.79%. Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 309.26%. Given Precision BioSciences' higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Relmada Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Relmada Therapeutics' return on equity of -71.22% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Precision BioSciences has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Precision BioSciences	$34.26M	5.93	-$45.72M	-$3.67	N/A

Relmada Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Relmada Therapeutics and Relmada Therapeutics both had 4 articles in the media. Precision BioSciences' average media sentiment score of 0.63 beat Relmada Therapeutics' score of 0.57 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Relmada Therapeutics beats Precision BioSciences on 8 of the 15 factors compared between the two stocks.

How does Precision BioSciences compare to Climb Bio?

Precision BioSciences (NASDAQ:DTIL) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Precision BioSciences has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.93	-$45.72M	-$3.67	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Precision BioSciences has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market. Comparatively, Climb Bio has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market.

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Climb Bio had 1 more articles in the media than Precision BioSciences. MarketBeat recorded 5 mentions for Climb Bio and 4 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.63 beat Climb Bio's score of 0.37 indicating that Precision BioSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has a net margin of 0.00% compared to Precision BioSciences' net margin of -96.73%. Climb Bio's return on equity of -31.45% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Climb Bio	N/A	-31.45%	-30.39%

Precision BioSciences presently has a consensus price target of $32.25, indicating a potential upside of 309.26%. Climb Bio has a consensus price target of $21.73, indicating a potential upside of 63.49%. Given Precision BioSciences' higher probable upside, research analysts plainly believe Precision BioSciences is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Summary

Climb Bio beats Precision BioSciences on 9 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Coeptis Therapeutics had 2 more articles in the media than Precision BioSciences. MarketBeat recorded 6 mentions for Coeptis Therapeutics and 4 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.63 beat Coeptis Therapeutics' score of 0.14 indicating that Precision BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Precision BioSciences has a consensus price target of $32.25, indicating a potential upside of 309.26%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by insiders. Comparatively, 2.7% of Precision BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Coeptis Therapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market. Comparatively, Precision BioSciences has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Precision BioSciences has a net margin of -96.73% compared to Coeptis Therapeutics' net margin of -810.04%. Precision BioSciences' return on equity of -85.37% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
Precision BioSciences	-96.73%	-85.37%	-37.34%

Coeptis Therapeutics has higher earnings, but lower revenue than Precision BioSciences. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	454.55	-$11.92M	-$2.52	N/A
Precision BioSciences	$34.26M	5.93	-$45.72M	-$3.67	N/A

Summary

Precision BioSciences beats Coeptis Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Precision BioSciences compare to Aclaris Therapeutics?

Precision BioSciences (NASDAQ:DTIL) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

Precision BioSciences has a net margin of -96.73% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Precision BioSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-85.37%	-37.34%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

Precision BioSciences has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 2.7% of Precision BioSciences shares are owned by company insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Precision BioSciences has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26M	5.93	-$45.72M	-$3.67	N/A
Aclaris Therapeutics	$7.83M	95.25	-$64.92M	-$0.56	N/A

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 309.26%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 115.36%. Given Precision BioSciences' higher possible upside, equities analysts clearly believe Precision BioSciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

In the previous week, Precision BioSciences had 2 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 4 mentions for Precision BioSciences and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.93 beat Precision BioSciences' score of 0.63 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precision BioSciences	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Precision BioSciences and Aclaris Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Precision BioSciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DTIL vs. The Competition

Export

Metric	Precision BioSciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$202.81M	$3.67B	$6.79B	$12.59B
Dividend Yield	N/A	2.21%	2.66%	6.15%
P/E Ratio	-2.15	21.28	27.67	25.27
Price / Sales	5.93	324.37	533.25	101.18
Price / Cash	N/A	141.54	47.99	59.26
Price / Book	1.96	8.71	10.96	6.62
Net Income	-$45.72M	$23.87M	$3.57B	$336.83M
7 Day Performance	16.74%	4.34%	2.88%	3.19%
1 Month Performance	24.68%	6.62%	3.69%	0.86%
1 Year Performance	84.98%	61.64%	34.39%	27.51%

Precision BioSciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DTIL Precision BioSciences	2.4783 of 5 stars	$7.88 +0.3%	$32.25 +309.3%	+90.8%	$202.81M	$34.26M	N/A	200	News Coverage
ALLO Allogene Therapeutics	3.2068 of 5 stars	$2.07 -1.4%	$8.52 +311.7%	+78.8%	$714.46M	$20K	N/A	310	Positive News
RLMD Relmada Therapeutics	2.1502 of 5 stars	$6.77 -1.7%	$12.00 +77.3%	+937.2%	$710.11M	N/A	N/A	10
CLYM Climb Bio	2.8676 of 5 stars	$12.30 +1.0%	$21.73 +76.6%	+1,016.8%	$704.30M	N/A	N/A	9	News Coverage
ZSQR Coeptis Therapeutics	0.1638 of 5 stars	$13.38 -9.0%	N/A	+62.7%	$688.13M	$1.36M	N/A	2	News Coverage Short Interest Increase Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DTIL) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Precision BioSciences (DTIL) Competitors

DTIL vs. ALLO, RLMD, CLYM, ZSQR, and ACRS

How does Precision BioSciences compare to Allogene Therapeutics?

Summary

How does Precision BioSciences compare to Relmada Therapeutics?

Summary

How does Precision BioSciences compare to Climb Bio?

Summary

How does Precision BioSciences compare to Coeptis Therapeutics?

Summary

How does Precision BioSciences compare to Aclaris Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Precision BioSciences (DTIL) Competitors

DTIL vs. ALLO, RLMD, CLYM, ZSQR, and ACRS

How does Precision BioSciences compare to Allogene Therapeutics?

Which has more risk and volatility, DTIL or ALLO?

Do institutionals and insiders hold more shares of DTIL or ALLO?

Which has better valuation and earnings, DTIL or ALLO?

Do analysts prefer DTIL or ALLO?

Does the media prefer DTIL or ALLO?

Is DTIL or ALLO more profitable?

Summary

How does Precision BioSciences compare to Relmada Therapeutics?

Do analysts rate RLMD or DTIL?

Is RLMD or DTIL more profitable?

Which has better earnings and valuation, RLMD or DTIL?

Which has more volatility & risk, RLMD or DTIL?

Do insiders & institutionals believe in RLMD or DTIL?

Does the media refer more to RLMD or DTIL?

Summary

How does Precision BioSciences compare to Climb Bio?

Which has better earnings and valuation, DTIL or CLYM?

Which has more risk and volatility, DTIL or CLYM?

Do insiders and institutionals believe in DTIL or CLYM?

Does the media prefer DTIL or CLYM?

Is DTIL or CLYM more profitable?

Do analysts rate DTIL or CLYM?

Summary

How does Precision BioSciences compare to Coeptis Therapeutics?

Does the media favor ZSQR or DTIL?

Do analysts recommend ZSQR or DTIL?

Do insiders & institutionals hold more shares of ZSQR or DTIL?

Which has more risk & volatility, ZSQR or DTIL?

Is ZSQR or DTIL more profitable?

Which has better valuation and earnings, ZSQR or DTIL?

Summary

How does Precision BioSciences compare to Aclaris Therapeutics?

Is DTIL or ACRS more profitable?

Which has more risk and volatility, DTIL or ACRS?

Do insiders and institutionals hold more shares of DTIL or ACRS?

Which has stronger valuation and earnings, DTIL or ACRS?

Do analysts recommend DTIL or ACRS?

Does the media prefer DTIL or ACRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DTIL vs. The Competition

Precision BioSciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools